Principal Securities Inc. Acquires 2,209 Shares of Cencora, Inc. (NYSE:COR)

Principal Securities Inc. increased its holdings in Cencora, Inc. (NYSE:COR - Free Report) by 11.9% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 20,821 shares of the company's stock after purchasing an additional 2,209 shares during the period. Principal Securities Inc.'s holdings in Cencora were worth $4,678,000 at the end of the most recent quarter.

Several other hedge funds have also recently added to or reduced their stakes in COR. Pacer Advisors Inc. increased its holdings in shares of Cencora by 6,855.3% during the third quarter. Pacer Advisors Inc. now owns 2,065,374 shares of the company's stock worth $464,874,000 after buying an additional 2,035,679 shares in the last quarter. Wellington Management Group LLP boosted its position in shares of Cencora by 7.0% during the third quarter. Wellington Management Group LLP now owns 5,193,386 shares of the company's stock worth $1,168,927,000 after purchasing an additional 338,452 shares in the last quarter. Nordea Investment Management AB raised its holdings in shares of Cencora by 40.2% during the fourth quarter. Nordea Investment Management AB now owns 1,077,272 shares of the company's stock worth $243,173,000 after acquiring an additional 308,773 shares during the period. Two Sigma Advisers LP raised its holdings in shares of Cencora by 21.7% during the third quarter. Two Sigma Advisers LP now owns 1,638,400 shares of the company's stock worth $368,771,000 after acquiring an additional 292,600 shares during the period. Finally, State Street Corp increased its stake in Cencora by 3.8% in the 3rd quarter. State Street Corp now owns 8,045,896 shares of the company's stock valued at $1,810,970,000 after buying an additional 291,867 shares during the last quarter. Institutional investors and hedge funds own 97.52% of the company's stock.

Analyst Ratings Changes

Several equities research analysts have issued reports on COR shares. Wells Fargo & Company lifted their price target on shares of Cencora from $237.00 to $251.00 and gave the company an "equal weight" rating in a research note on Wednesday, January 29th. Robert W. Baird lifted their target price on shares of Cencora from $287.00 to $292.00 and gave the stock an "outperform" rating in a report on Thursday, November 7th. Barclays boosted their price objective on shares of Cencora from $263.00 to $290.00 and gave the company an "overweight" rating in a report on Thursday, November 7th. UBS Group boosted their target price on shares of Cencora from $275.00 to $285.00 and gave the company a "buy" rating in a research report on Thursday, November 7th. Finally, Evercore ISI boosted their target price on shares of Cencora from $270.00 to $280.00 and gave the company an "outperform" rating in a research report on Thursday, February 6th. Two research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, Cencora presently has an average rating of "Moderate Buy" and an average target price of $277.90.

Cencora Stock Down 0.8 %

NYSE:COR traded down $2.00 during trading hours on Thursday, reaching $243.42. The company had a trading volume of 1,188,505 shares, compared to its average volume of 1,501,455. The firm has a market cap of $47.20 billion, a price-to-earnings ratio of 34.63, a P/E/G ratio of 1.29 and a beta of 0.49. The business's 50-day simple moving average is $239.11 and its two-hundred day simple moving average is $237.42. Cencora, Inc. has a twelve month low of $214.77 and a twelve month high of $262.26. The company has a quick ratio of 0.54, a current ratio of 0.92 and a debt-to-equity ratio of 16.40.

Cencora (NYSE:COR - Get Free Report) last issued its quarterly earnings data on Wednesday, February 5th. The company reported $3.73 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $3.50 by $0.23. Cencora had a net margin of 0.46% and a return on equity of 328.62%. On average, equities analysts expect that Cencora, Inc. will post 15.37 earnings per share for the current year.

Cencora Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Monday, March 3rd. Investors of record on Friday, February 14th will be given a dividend of $0.55 per share. This represents a $2.20 dividend on an annualized basis and a dividend yield of 0.90%. The ex-dividend date of this dividend is Friday, February 14th. Cencora's payout ratio is currently 31.29%.

Insider Activity at Cencora

In related news, Chairman Steven H. Collis sold 50,000 shares of the firm's stock in a transaction dated Monday, November 25th. The shares were sold at an average price of $243.97, for a total transaction of $12,198,500.00. Following the transaction, the chairman now directly owns 326,557 shares of the company's stock, valued at $79,670,111.29. This trade represents a 13.28 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Silvana Battaglia sold 1,678 shares of Cencora stock in a transaction dated Friday, December 20th. The stock was sold at an average price of $228.72, for a total transaction of $383,792.16. Following the completion of the sale, the executive vice president now directly owns 20,329 shares in the company, valued at approximately $4,649,648.88. This represents a 7.62 % decrease in their position. The disclosure for this sale can be found here. 10.80% of the stock is owned by insiders.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.